1. [Untitled]
- Author
-
Roger M. Lane and Glen B. Baker
- Subjects
Drug ,Bupropion ,medicine.medical_specialty ,Chemistry ,media_common.quotation_subject ,Trazodone ,Cell Biology ,General Medicine ,Pharmacology ,Mianserin ,Viloxazine ,Amine transport ,Cellular and Molecular Neuroscience ,Drug development ,medicine ,Enantiomer ,Psychiatry ,medicine.drug ,media_common - Abstract
1. Many drugs used to treat psychiatric disorders contain a chiral center or a center of unsaturation and are marketed as a mixture of the resultant enantiomers or geometric isomers, respectively. These enantiomers or geometric isomers may differ markedly with regard to their pharmacodynamic and/or pharmacokinetic properties. 2. Examples of the effects of chiral centers or geometric centers on such properties are given for drugs from the following classes: antidepressants (tricyclics, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, viloxazine, bupropion, trazodone, mianserin, venlaflaxine); benzodiazepines, zoplicone, and antipsychotics. 3. As described in this review, there are several notable examples of psychiatric drugs currently available where the individual enantiomers or geometric isomers differ considerably with regard to factors such as effects on amine transport systems, interactions with receptors and metabolizing enzymes, and clearance rates from the body. Indeed, relatively recent developments in analytical and preparative resolution of racemic and geometric drug mixtures and increased interest in developing new drugs which interact with specific targets, which have been described in detail at the molecular level, have resulted in increased emphasis on stereochemistry in drug development.
- Published
- 1999
- Full Text
- View/download PDF